Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, has announced the closing of its initial public offering (“IPO”). The IPO consisted of a total of 4,025,000 shares — 3,500,000 shares of common stock combined with 525,000 additional shares made available through the exercise of the underwriters’ option to purchase additional common stock shared. All the shares were offered at the price of $6 per share, and resulted in $24.15 million for the company, before underwiring discounts, commissions and other related expenses were deducted. For the offering, Roth Capital Partners acted as sole book-running manager and representative of the underwriters.
To view the full press release, visit https://ibn.fm/twPg7
About Vivos Therapeutics Inc.
Vivos Therapeutics Inc. is a medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective nonsurgical, noninvasive, nonpharmaceutical, and low-cost solution for patients with sleep disordered breathing (“SDB”), including mild-to-moderate obstructive sleep apnea (“OSA”). The company believes its products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (“CPAP”). For more information about the company, please visit www.VivosLife.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.